Interventional Oncology http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology <h1 class="header1">Interventional Oncology News</h1> en BIBA Medical Ltd Tue, 23 Sep 2014 17:22:08 GMT http://blogs.law.harvard.edu/tech/rss 3360 Affino 5 RSS Generator webeditor@bibamedical.com Sirtex expands business into Brazil http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil <div style="display:block;"> <div id="ImageThumb1" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/015/sirtex_thumb_Thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser1" style="float:left;"> Sirtex has announced the expansion of its business in Latin America. Sirtex’s SIR-Spheres microspheres are now available to treat inoperable liver tumours in Brazil. </div> </div> Tue, 09 Sep 2014 09:32:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/first-patient-enrolled-in-global-phase-iii-optima-study-of-thermodox-in-primary-liver-cancer <div style="display:block;"> <div id="ItemTeaser2" style="float:left;"> Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea. </div> </div> Fri, 05 Sep 2014 09:40:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/first-patient-enrolled-in-global-phase-iii-optima-study-of-thermodox-in-primary-liver-cancer DC Bead approved by China Food and Drug Administration http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/dc-bead-approved-by-china-food-and-drug-administration <div style="display:block;"> <div id="ImageThumb3" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/dc-bead-approved-by-china-food-and-drug-administration"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/DC_Bead_thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser3" style="float:left;"> BTG and its partner SciClone Pharmaceuticals have announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularised tumours. </div> </div> Tue, 02 Sep 2014 11:15:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/dc-bead-approved-by-china-food-and-drug-administration Study identifies tumour-promoting role of EGFR present in liver macrophages http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/study-identifies-tumour-promoting-role-of-egfr-present-in-liver-macrophages- <div style="display:block;"> <div id="ItemTeaser4" style="float:left;"> A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour. </div> </div> Mon, 01 Sep 2014 11:48:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/study-identifies-tumour-promoting-role-of-egfr-present-in-liver-macrophages- The microenvironment of solid tumours matters http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/the-microenvironment-of-solid-tumours-matters <div style="display:block;"> <div id="ImageThumb5" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/the-microenvironment-of-solid-tumours-matters"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/arepally_thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser5" style="float:left;"> Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents, writes Aravind Arepally. </div> </div> Fri, 08 Aug 2014 16:28:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/the-microenvironment-of-solid-tumours-matters